综述：溃疡性结肠炎患者使用托法替布治疗的风险分层 - Suppr

Review: Risk Stratification of Patients With Ulcerative Colitis for Treatment With Tofacitinib.

作者信息

Danese Silvio, Panés Julian, Dubinsky Marla, Guo Xiang, Yndestad Arne, Schreiber Stefan, Chaparro María

机构信息

Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy.

Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain.

出版信息

Crohns Colitis 360. 2024 Sep 19;6(4):otae049. doi: 10.1093/crocol/otae049. eCollection 2024 Oct.

DOI:10.1093/crocol/otae049

PMID:39372098

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11447936/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc85/11447936/4eb6947c090c/otae049_fig1.jpg

相似文献

Review: Risk Stratification of Patients With Ulcerative Colitis for Treatment With Tofacitinib.综述：溃疡性结肠炎患者使用托法替布治疗的风险分层

Crohns Colitis 360. 2024 Sep 19;6(4):otae049. doi: 10.1093/crocol/otae049. eCollection 2024 Oct.

Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis.比较托法替布和维多珠单抗在抗TNF治疗失败的溃疡性结肠炎患者中的真实世界证据

Inflamm Bowel Dis. 2024 Apr 3;30(4):554-562. doi: 10.1093/ibd/izad115.

The current role of Tofacitinib in acute severe ulcerative colitis in adult patients: A systematic review.托法替布在成年患者急性重症溃疡性结肠炎中的当前作用：一项系统评价。

Dig Liver Dis. 2023 Oct;55(10):1311-1317. doi: 10.1016/j.dld.2023.05.021. Epub 2023 Jun 12.

Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.奥卡维妥昔单抗维持治疗溃疡性结肠炎患者的治疗结局建模：OCTAVE 临床项目数据的事后分析。

Adv Ther. 2023 Oct;40(10):4440-4459. doi: 10.1007/s12325-023-02603-0. Epub 2023 Jul 31.

Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program.在溃疡性结肠炎项目中接受托法替尼治疗的溃疡性结肠炎患者中的艰难梭菌感染。

Inflamm Bowel Dis. 2023 May 2;29(5):744-751. doi: 10.1093/ibd/izac139.

Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis.托法替布挽救治疗用于因皮质类固醇和生物制剂难治性溃疡性结肠炎住院的儿童。

J Pediatr Gastroenterol Nutr. 2022 Dec 1;75(6):724-730. doi: 10.1097/MPG.0000000000003616. Epub 2022 Sep 19.

Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study.托法替布治疗溃疡性结肠炎患者的真实疗效及安全性：一项KASID多中心队列研究

Therap Adv Gastroenterol. 2023 Mar 18;16:17562848231154103. doi: 10.1177/17562848231154103. eCollection 2023.

Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience.托法替布治疗儿童溃疡性结肠炎：一项回顾性多中心研究经验

Inflamm Bowel Dis. 2025 Feb 6;31(2):425-431. doi: 10.1093/ibd/izae112.

Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials.托法替布治疗溃疡性结肠炎停药后再治疗的疗效和安全性：OCTAVE 临床试验结果。

J Crohns Colitis. 2021 Nov 8;15(11):1852-1863. doi: 10.1093/ecco-jcc/jjab065.

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience.托法替布治疗溃疡性结肠炎：从临床试验到真实世界经验的疗效与安全性

Therap Adv Gastroenterol. 2019 May 16;12:1756284819848631. doi: 10.1177/1756284819848631. eCollection 2019.

引用本文的文献

Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data.接受JAK抑制剂治疗的炎症性肠病患者的癌症风险：来自试验和真实世界数据的可靠证据。

Cancers (Basel). 2025 Feb 21;17(5):735. doi: 10.3390/cancers17050735.

Tofacitinib and budesonide treatment affect stemness and chemokine release in IBD patient-derived colonoids.托法替布和布地奈德治疗影响炎症性肠病患者来源的类结肠细胞的干性和趋化因子释放。

Sci Rep. 2025 Jan 30;15(1):3753. doi: 10.1038/s41598-025-86314-2.

本文引用的文献

Association Between Smoking Status and the Efficacy and Safety of Tofacitinib in Patients with Ulcerative Colitis.吸烟状态与托法替布治疗溃疡性结肠炎患者的疗效及安全性之间的关联

Crohns Colitis 360. 2024 Jan 20;6(1):otae004. doi: 10.1093/crocol/otae004. eCollection 2024 Jan.

Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors.管理与 JAK 抑制剂相关的心血管和癌症风险。

Drug Saf. 2023 Nov;46(11):1049-1071. doi: 10.1007/s40264-023-01333-0. Epub 2023 Jul 25.

Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.接受托法替尼治疗的溃疡性结肠炎患者基于基线心血管风险的主要不良心血管事件：OCTAVE 临床项目的数据。

J Crohns Colitis. 2023 Nov 24;17(11):1761-1770. doi: 10.1093/ecco-jcc/jjad104.

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.鉴定两种托法替布亚群与 TNF 抑制剂的相对风险不同：一项开放性标签、随机对照研究 ORAL Surveillance 的分析。

Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.

Risk of Cancer in Patients with Inflammatory Bowel Diseases and Keys for Patient Management.炎症性肠病患者的癌症风险及患者管理要点

Cancers (Basel). 2023 Jan 31;15(3):871. doi: 10.3390/cancers15030871.

Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program.评估溃疡性结肠炎临床项目中按年龄分层的托法替布的安全性和疗效。

Inflamm Bowel Dis. 2023 Jan 5;29(1):27-41. doi: 10.1093/ibd/izac084.

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.托法替尼与肿瘤坏死因子抑制剂治疗伴或不伴动脉粥样硬化性心血管疾病史的类风湿关节炎患者的主要不良心血管事件风险：来自 ORAL Surveillance 的事后分析。

Ann Rheum Dis. 2023 Jan;82(1):119-129. doi: 10.1136/ard-2022-222259. Epub 2022 Sep 22.

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.托法替布治疗溃疡性结肠炎：全球临床项目长达 7.8 年的安全性汇总数据综合摘要。

J Crohns Colitis. 2023 Apr 3;17(3):338-351. doi: 10.1093/ecco-jcc/jjac141.

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.托法替尼治疗类风湿关节炎与心血管和癌症风险。

N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927.

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.托法替布治疗溃疡性结肠炎的安全性和疗效：OCTAVE Open 的最终分析，一项开放性、长期扩展研究，治疗时间长达 7.0 年。

Aliment Pharmacol Ther. 2022 Feb;55(4):464-478. doi: 10.1111/apt.16712. Epub 2021 Dec 1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Review: Risk Stratification of Patients With Ulcerative Colitis for Treatment With Tofacitinib.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献